Benign prostatic hyperplasia: Epidemiology, economics and evaluation

Canadian Journal of Urology

Volumn 22, Issue , 2015, Pages 1-6

  Vuichoud, Camille ^a   Loughlin, Kevin R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Benign prostatic hypertrophy; Lower urinary tract symptoms

Indexed keywords

AGE; AGED; ECONOMICS; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOWER URINARY TRACT SYMPTOMS; MALE; NEEDLE BIOPSY; PROCEDURES; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; AGED; BIOPSY, NEEDLE; HEALTH CARE COSTS; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 84981215057     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3): 474-479.
2. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 1999; 161(4):1174-1179.
3. Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000;163(9):13-20.
4. Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol 1968;99(5):639-645.
5. Glynn RJ, Campion EW et al. The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 1985;121(1):78-90.
6. Araki H, Wantanabe H, Mishina T, Nakao M. High-risk group for benign prostatic hypertrophy. Prostate 1983;4(3):253-264.
7. Jacobsen SJ, Jacobson DJ, Rohe DE et al. Frequency of sexual activity and prostatic health: fact or fairy tale? Urology 2003;61(2): 348-353.
8. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47(6):838-845.
9. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51(5):1202-1216.
10. Gandaglia G, Briganti A, Gontero P et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112(4):432-441.
11. Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PloS One 2014;9(1):e85588.
12. Vignozzi L, Gacci M, Cella I et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013;73(13):1391-1402.
13. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2013;189(1 Suppl): S102-S106.
14. Mondul AM, Giovannucci E, Platz EA. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol 2014;191(3):715-721.
15. Sarma AV, St. Sauver JL, Hollingsworth JM et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology 2012;79(1): 102-108.
16. Wehrberger C, Temmi C, Cutjahr G et al. Is there an association between lower urinary tract symptoms and cardiovascular risk in men? A cross sectional and longitudinal analysis. Urology 2011; 78(5):1063-1067.
17. Gacci, M, Corona G, Vignozzi L et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and metaanalysis. BJU Int 2015;115(1):24-31.
18. Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sportsmed 2009;37(4):75-83.
19. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008; 53(6):1228-1235.
20. Muller RL, Gerber L, Mopreira DM et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol 2013;63(6):1115-1121.
21. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol 2014; 192(1):16-23.
22. Partin AW, Page WF, Lee BR et al. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology 1994;44(5):646-650.
23. Sanda MG, Doehring CB, Binkowitz B et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997; 157(3):876-879.
24. Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 2006;7(4):272-281.
25. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005;173(4):1309-1313.
26. Amerson D. Urolift for BPH: Changing the Game In BPH Care, Presentation at AACU State Advocacy Conference, Chicago, IL Sept 18-19, 2015.
27. From the Centers for Disease Control and Prevention. Public health and aging: trends in aging-United States and worldwide. JAMA 2003;289(11):1371-1373.
28. Andriole GL, Bruchovsky N, Chung LW et al. Dilydrotestodterone and the prostate: the scientific rationale for 5 alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172(4 Pt 1):1399-1403.
29. Barrack ER, Berry SJ. DNA synthesis in the canine prostate:effects of androgen and estrogen treatment. Prostate 1987;10(1): 45-56.
30. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin N Amer 2008;35(1):109-115.
31. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B. Increased expression of lymphocyte-derived cytokines in benign prostate tissue, identification of the producing cell types and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52(1):43-48.
32. Lee KK, Peeh ID. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004;172(5 Pt 1):1784-1791.
33. McVary KT, Roehrborn CG, Auins AL, Barry MJ et al. Update on AUA guidelines on the management of benign prostatic hyperplasia. J Urol 2011;185(5):1793-1803.
34. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006;97(Suppl 2):3-6; discussion 21-22.
35. Fukuta F, Masumori N, Mori M, Tsukamoto T. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study. BJU Int 2012;110(7): 1023-1029.
36. Martin S, Lange K, Haven MY et al. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014;191(1):130-137.
37. Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 2012;109(1):84-87.
38. Kok ET, Schouten BW, Bohnen AM et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 2009;181(2):710-716.
39. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006;12(5 Suppl):S122-S128.
40. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007;178(2):395-401.
41. Wuerstle MC, Van Den Eedern SK, Poon KT et al. Contribution of common medications to lower urinary tract symptoms in men. Arch Intern Med 2011;171(18):1680-1682.
42. Plat EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 2002;59(6):877-883.
43. Donovan J L, Kay ME, Peters TJ et al. Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society-Benign Prostatic Hyperplasia. Br J Urol 1997;80(5): 712-721.
44. Gratzke C, Bachmann A, Descazeaud A et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015; 67(6):1099-1109.
45. Nickel JC, Herschorn S, Corcos J et al. Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol 2005; 12(3):2677-2683.
46. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148(5):1549-1557; discussion 1564.
47. Chung RY, Leung JC, Chan DC et al. Lower urinary tract symptoms (LUTS) as a risk factor for depressive symptoms in elderly men: results from a large prospective study in Southern Chinese men. PloS One 2013;8(9):e76017.
48. O'Leary MP. LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 2000;56(5 Suppl 1):7-11.
49. Wein AJ, Coyne KS, Tubaro A et al. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int 2009; 103(Suppl 3):33-41.
50. Descazeaud A, de la Taille A, Giuliano F, Desgrandchamps F, Doridot G. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.]. Prog Urol 2015:25(3):115-127.
51. Levitt JM, Slawin KM. Prostate-specific antigen and prostatespecific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Urol Rep 2007;8(4):269-274.
52. Cannon GW, Getzenberg RH. Biomarkers for benign prostatic hyperplasia progression. Curr Urol Rep 2008;9(4):279-283.
53. Brown CT, Emberton M. Self-management for men with lower urinary tract symptoms. Curr Urol Rep 2009;10(4):261-266.
54. Hollingsworth JM, Hollenbeck BK, Daignault S, Kim SP, Wei JT. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists. J Urol 2009;182(5): 2410-2414.
55. Wei J, Miner MM, Stecks WD et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol 2011;186(3):971-976.
56. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999;83(4): 410-415.
57. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009;103(Suppl 3)12-23.
58. Davidson JH, Chutka DS. Benign prostatic hyperplasia: treat or wait? J Fam Pract 2008;57(7)454-463.
59. Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol 2015;22(Suppl 1): 7-17.
60. Keehn A, Lowe FC. Complementary and alternative medications for benign prostatic hyperplasia. Can J Urol 2015;22(Suppl 1): 18-23.